Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Astellas Ties Up with Maxygen to Develop Drugs for Autoimmune Diseases, Transplant Rejection
September 29, 2008
- More Prescriptions than Expected Prohibit Use of Generics: Mr Urushibata
September 29, 2008
- Erbitux Launched by Merck Serono and Bristol-Myers
September 29, 2008
- Draft Ordinance Published in Preparation for Full Enforcement of Amended PAL
September 29, 2008
- Japanese Pharma Industry Group Visits UCB
September 22, 2008
- RAD001 Granted Priority Review Status in the US
September 22, 2008
- Meiji Seika, Meiji Dairy to Integrate Businesses
September 22, 2008
- Will Distribution Practices Be Improved? Part 2
September 22, 2008
- NovoRapid 30 Mix Has Turned Out to Be Global Blockbuster: Novo Nordisk Pharma
September 22, 2008
- Kissei Licenses Monoclonal Antibody from Y's Therapeutics
September 22, 2008
- Global Market for Monoclonal Antibodies to Expand to $49 Bil. in 2013: Datamonitor
September 22, 2008
- Eli Lilly Japan Aims at $1 Bil. in 2010, $2Bil. in 2015: Mr Zulueta
September 22, 2008
- Delegates Criticize JPA Leaders over Qualification for Store Managers
September 22, 2008
- REGULATORY NEWS IN BRIEF
September 22, 2008
- NEW PRODUCTS
September 22, 2008
- Bayer to Begin PIII Trial of Rivaroxaban Ahead of Schedule
September 22, 2008
- Growell HD to Open More Drugstores with Dispensing Services
September 22, 2008
- Yakult Applies for New Indication for Oxaliplatin
September 22, 2008
- A Case of Diagnosis and Treatment of Effort Angina in Japan
September 22, 2008
- Approval May Be Delayed due to Deficiency in Application Dossiers: PMDA Reviewer
September 22, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…